Shrushti Shah
Overview
Explore the profile of Shrushti Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seigel L, Shoaib S, Maughn K, Foster M, Shah S, Batchu L, et al.
J Dermatolog Treat
. 2024 Jun;
35(1):2365820.
PMID: 38914420
Purpose: Providers who treat patients with psoriasis are unevenly distributed across the United States, with more in urban than rural areas. This retrospective claims analysis characterized disparities in access to...
2.
Shearer J, Shah S, Shen-Tu G, Schlicht K, Laudes M, Mu C
ACS Pharmacol Transl Sci
. 2024 Apr;
7(4):991-1001.
PMID: 38665607
Human gut microbiota are recognized as critical players in both metabolic disease and drug metabolism. However, medication-microbiota interactions in cardiometabolic diseases are not well understood. To gain a comprehensive understanding...
3.
Shearer J, Shah S, MacInnis M, Shen-Tu G, Mu C
Nutrients
. 2024 Mar;
16(6).
PMID: 38542697
Oral iron supplementation is the first-line treatment for addressing iron deficiency, a concern particularly relevant to women who are susceptible to sub-optimal iron levels. Nevertheless, the impact of iron supplementation...
4.
Cohen A, Noxon V, Dhamane A, Shah S, Hines D, Alfred T, et al.
Curr Med Res Opin
. 2024 Feb;
40(3):545-553.
PMID: 38332714
Objective: Patients with active cancer and venous thromboembolism (VTE) have elevated risk of recurrent VTE (rVTE) and major bleeding (MB). The risk is even higher within those with a prior...
5.
Cohen A, Noxon V, Dhamane A, Shah S, Hines D, Alfred T, et al.
Future Oncol
. 2024 Jan;
20(9):521-532.
PMID: 38197229
Treatment effects among anticoagulant-treated patients with venous thromboembolism (VTE) and cancer across tumor types were evaluated. Patients initiating an anticoagulant within 30 days after VTE were identified. After inverse probability...
6.
Cohen A, Noxon V, Dhamane A, Bruette R, Shah S, Hines D, et al.
Thromb Res
. 2023 May;
226:117-126.
PMID: 37146438
Introduction: Patients with brain cancer are at a high risk of developing venous thromboembolism (VTE) and are underrepresented in clinical trials. This study compared the risk of recurrent VTE (rVTE),...
7.
Shah S, Mu C, Moossavi S, Shen-Tu G, Schlicht K, Rohmann N, et al.
FASEB J
. 2023 Mar;
37(4):e22882.
PMID: 36943402
Physical inactivity is one of the leading causes of chronic metabolic disease including obesity. Increasing physical activity (PA) has been shown to improve cardiometabolic and musculoskeletal health and to be...
8.
Dhamane A, Shah S, Noxon V, Bruette R, Ferri M, Liu X, et al.
Thromb Res
. 2023 Feb;
224:52-59.
PMID: 36848784
Background: Patients with venous thromboembolism (VTE) and cancer are at higher risk of recurrent VTE and mortality. Clinical guidelines recommend anticoagulant treatment for these patients. This study assessed trends in...
9.
Fillier T, Shah S, Doody K, Pham T, Aubry I, Tremblay M, et al.
Sci Rep
. 2022 Aug;
12(1):14355.
PMID: 35999262
Communication between gut microbiota and the brain is an enigma. Alterations in the gut microbial community affects enteric metabolite levels, such as short chain fatty acids (SCFAs). SCFAs have been...
10.
Henneke L, Schlicht K, Andreani N, Hollstein T, Demetrowitsch T, Knappe C, et al.
Gut Microbes
. 2022 Apr;
14(1):2057778.
PMID: 35435797
Recent rodent microbiome experiments suggest that besides . are important in type 2 diabetes and obesity development. In the present translational human study, we aimed to characterize in our European...